Shattuck Labs

Shattuck Labs is a biopharmaceutical company developing monoclonal antibody therapies targeting the DR3 immune receptor for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated conditions. The company's lead candidate, SL-325, is in clinical-stage development and designed to block the interaction between TL1A and DR3 expressed on immune cells.